Mineralys Therapeutics Inc [MLYS] stock is trading at $37.02, up 2.72%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The MLYS shares have gain 2.27% over the last week, with a monthly amount drifted -16.36%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Mineralys Therapeutics Inc [NASDAQ: MLYS] stock has seen the most recent analyst activity on June 11, 2025, when Jefferies initiated its Hold rating and assigned the stock a price target of $15. Previously, H.C. Wainwright started tracking the stock with Buy rating on July 10, 2024, and set its price target to $30. On April 02, 2024, Goldman initiated with a Buy rating and assigned a price target of $30 on the stock. Wells Fargo started tracking the stock assigning an Overweight rating and suggested a price target of $27 on March 07, 2023. Stifel initiated its recommendation with a Buy and recommended $45 as its price target on March 07, 2023. Guggenheim started tracking with a Buy rating for this stock on March 07, 2023, and assigned it a price target of $32. In a note dated March 07, 2023, Evercore ISI initiated an Outperform rating.
Mineralys Therapeutics Inc [MLYS] stock has fluctuated between $8.24 and $47.65 over the past year. Currently, Wall Street analysts expect the stock to reach $52 within the next 12 months. Mineralys Therapeutics Inc [NASDAQ: MLYS] shares were valued at $37.02 at the most recent close of the market. An investor can expect a potential return of 40.46% based on the average MLYS price forecast.
Analyzing the MLYS fundamentals
Gross Profit Margin for this corporation currently stands at -0.26% with Operating Profit Margin at -5972.53%, Pretax Profit Margin comes in at -5610.97%, and Net Profit Margin reading is -5610.97%. To continue investigating profitability, this company’s Return on Assets is posted at -0.57, Equity is -0.7 and Total Capital is -0.65.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 36.22 points at the first support level, and at 35.42 for the second support level. However, for the 1st resistance point, the stock is sitting at 37.82, and for the 2nd resistance point, it is at 38.62.
Ratios To Look Out For
For context, Mineralys Therapeutics Inc’s Current Ratio is 25.50. Also, the Quick Ratio is 25.50, while the Cash Ratio stands at 4.59.
Transactions by insiders
Recent insider trading involved Slingsby Brian Taylor, Director, that happened on Nov 20 ’25 when 1.0 million shares were sold. Affiliate, Catalys Pacific Fund, LP completed a deal on Nov 20 ’25 to buy 1.0 million shares. Meanwhile, CFO and Secretary Levy Adam Scott sold 0.12 million shares on Nov 11 ’25.
